Dale

Dale Atkinson was diagnosed with Stage IV moderately differentiated oesophageal adenocarcinoma (HER2-negative) after a 9.2 cm tumour and extensive metastatic disease were identified in late 2024, with a prognosis of “inoperable and likely incurable.” What followed was not defiance but design. Dale continued NHS chemotherapy and immunotherapy while leading a precision-guided, clinician-supervised adjunct plan developed with Astron Health and Dr Hari Kuhan, using next-generation profiling and AI-assisted literature review. His care integrated carefully supervised adjuncts and repurposed medicines alongside standard oncology, resulting in a major clinical response and regression of metastatic nodes. Careful to call this correlation, not proof, Dale credits continuous medical oversight and integration within the system. He has since co-founded Beyond the Standard, is establishing The ClearPath Clinic, and shares lessons on resilience, evidence-aware care, and patient-clinician collaboration. As a podcast guest, he brings grounded insight and lived experience to conversations about cancer, adjuncts, and working constructively within modern medicine.